# AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses

> **NCT04392206** · PHASE1 · RECRUITING · sponsor: **Houssam Farres, M.D.** · enrollment: 15 (estimated)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** Adipose Derived Mesenchymal Stem Cells

## Key facts

- **NCT ID:** NCT04392206
- **Lead sponsor:** Houssam Farres, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-15
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04392206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04392206, "AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04392206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*